drugset / Trial / NCT01751984

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

NCT01751984

Phase 2 Completed 56 enrolled Esperion Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the Low-Density Lipoprotein-Cholesterol (LDL-C) lowering efficacy and safety of ETC-1002 versus placebo in participants with hypercholesterolemia and a history of statin intolerance.

Timeline

Start
2012-10-04
Primary completion
2013-05-01
Completion
2013-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bempedoic acid Small molecule 240 mg Oral

Indications